Cargando…
In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia
The novel aminopeptidase potentiated alkylating agent melflufen, was evaluated for activity in acute myeloid leukemia in a range of in vitro models, as well as in a patient derived xenograft study. All tested AML cell lines were highly sensitive to melflufen while melphalan was considerably less pot...
Autores principales: | Strese, Sara, Bashir Saadia, Hassan, Velander, Ebba, Haglund, Caroline, Höglund, Martin, Larsson, Rolf, Gullbo, Joachim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351636/ https://www.ncbi.nlm.nih.gov/pubmed/27974676 http://dx.doi.org/10.18632/oncotarget.13856 |
Ejemplares similares
-
Melflufen - a peptidase-potentiated alkylating agent in clinical trials
por: Wickström, Malin, et al.
Publicado: (2017) -
Preclinical activity of melflufen (J1) in ovarian cancer
por: Carlier, Charlotte, et al.
Publicado: (2016) -
In vitro and in vivo activity of melflufen (J1)in lymphoma
por: Delforoush, Maryam, et al.
Publicado: (2016) -
Effects of hypoxia on human cancer cell line chemosensitivity
por: Strese, Sara, et al.
Publicado: (2013) -
Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
por: Mateos, María-Victoria, et al.
Publicado: (2020)